HK1245107A1 - 多发性骨髓瘤的罗尼哌他组合治疗 - Google Patents

多发性骨髓瘤的罗尼哌他组合治疗 Download PDF

Info

Publication number
HK1245107A1
HK1245107A1 HK18104587.1A HK18104587A HK1245107A1 HK 1245107 A1 HK1245107 A1 HK 1245107A1 HK 18104587 A HK18104587 A HK 18104587A HK 1245107 A1 HK1245107 A1 HK 1245107A1
Authority
HK
Hong Kong
Prior art keywords
use according
melphalan
administered
roneparstat
kit
Prior art date
Application number
HK18104587.1A
Other languages
English (en)
Chinese (zh)
Inventor
拉尔夫‧D‧桑德森
拉爾夫‧D‧桑德森
维士努‧C‧普拉卡什‧C‧拉马尼
亚历山大‧诺塞达
維士努‧C‧普拉卡什‧C‧拉馬尼
保拉‧巴尔维里
亞歷山大‧諾塞達
保拉‧巴爾維里
Original Assignee
Leadiant Biosciences Sa In Liquidazione
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadiant Biosciences Sa In Liquidazione, The Uab Research Foundation filed Critical Leadiant Biosciences Sa In Liquidazione
Publication of HK1245107A1 publication Critical patent/HK1245107A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18104587.1A 2015-03-06 2016-03-03 多发性骨髓瘤的罗尼哌他组合治疗 HK1245107A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129221P 2015-03-06 2015-03-06
US62/129221 2015-03-06
US201562153899P 2015-04-28 2015-04-28
US62/153899 2015-04-28
PCT/IB2016/051196 WO2016142814A1 (en) 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma

Publications (1)

Publication Number Publication Date
HK1245107A1 true HK1245107A1 (zh) 2018-08-24

Family

ID=55521766

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104587.1A HK1245107A1 (zh) 2015-03-06 2016-03-03 多发性骨髓瘤的罗尼哌他组合治疗

Country Status (16)

Country Link
US (1) US10576101B2 (enExample)
EP (2) EP3265075B1 (enExample)
JP (1) JP2018512394A (enExample)
KR (1) KR20170138405A (enExample)
CN (1) CN107645954A (enExample)
AU (1) AU2016230859A1 (enExample)
BR (1) BR112017018869A2 (enExample)
CA (1) CA2978040A1 (enExample)
DK (1) DK3265075T3 (enExample)
ES (1) ES2715556T3 (enExample)
HK (1) HK1245107A1 (enExample)
HU (1) HUE042681T2 (enExample)
MX (1) MX2017011093A (enExample)
PL (1) PL3265075T3 (enExample)
PT (1) PT3265075T (enExample)
WO (1) WO2016142814A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CZ307433B6 (cs) 2001-09-12 2018-08-22 Leadiant Biosciences Sa Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
PL3265075T3 (pl) 2020-10-05
CN107645954A (zh) 2018-01-30
EP3265075B1 (en) 2018-12-12
US20180050061A1 (en) 2018-02-22
DK3265075T3 (en) 2019-04-08
ES2715556T3 (es) 2019-06-04
MX2017011093A (es) 2018-02-19
EP3453389A1 (en) 2019-03-13
US10576101B2 (en) 2020-03-03
HUE042681T2 (hu) 2019-07-29
BR112017018869A2 (pt) 2018-04-17
KR20170138405A (ko) 2017-12-15
CA2978040A1 (en) 2016-09-15
AU2016230859A1 (en) 2017-08-17
PT3265075T (pt) 2019-03-25
EP3265075A1 (en) 2018-01-10
WO2016142814A1 (en) 2016-09-15
JP2018512394A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
DK2582683T3 (en) TREATMENT OF Gout and Hyperuricemia
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
JP2024506825A (ja) Ｓ１ｐ受容体調節剤による処置の方法
WO2001054678A2 (en) Combination therapy for cancer
JP2025530190A (ja) アルツハイマー病治療のための免疫療法薬とｓｃｙｌｌｏ－イノシトールとの組み合わせ
HK1245107A1 (zh) 多发性骨髓瘤的罗尼哌他组合治疗
WO2021133862A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
NZ788615A9 (en) Dosing of a bruton's tyrosine kinase inhibitor
HK1189515B (en) Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib
HK1233169A1 (en) Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
HK1233169A (en) Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
HK1129853B (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
HK1189515A (en) Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib